The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Identifieur interne : 001360 ( Main/Corpus ); précédent : 001359; suivant : 001361The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Auteurs : Ensieh Vahedi ; Mostafa Ghanei ; Ali Ghazvini ; Hossein Azadi ; Morteza Izadi ; Yunes Panahi ; Saeid Fathi ; Mahmood Salesi ; Seyed Hassan Saadat ; Amir Hossein Ghazale ; Mohammad Rezapour ; Abolfazl Mozafari ; Nahid Zand ; Mohammadreza Raesi Parsaei ; Mohammad Hossein Ranjkesh ; Ramezan Jafari ; Fatemeh Movaseghi ; Enayat DarabiSource :
- Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [ 2008-2231 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Azithromycin (administration & dosage), COVID-19 (complications), COVID-19 (drug therapy), Drug Combinations (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Hydroxychloroquine (administration & dosage), Iran (MeSH), Length of Stay (MeSH), Levofloxacin (administration & dosage), Lopinavir (administration & dosage), Male (MeSH), Meropenem (administration & dosage), Middle Aged (MeSH), Naproxen (administration & dosage), Oseltamivir (administration & dosage), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), Prednisolone (administration & dosage), Retrospective Studies (MeSH), Ritonavir (administration & dosage), Treatment Outcome (MeSH), Vancomycin (administration & dosage).
- MESH :
- chemical , administration & dosage : Azithromycin, Hydroxychloroquine, Levofloxacin, Lopinavir, Meropenem, Naproxen, Oseltamivir, Prednisolone, Ritonavir, Vancomycin.
- geographic : Iran.
- complications : COVID-19.
- drug therapy : COVID-19, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- virology : Pneumonia, Viral.
- Adult, Aged, Drug Combinations, Drug Therapy, Combination, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Treatment Outcome.
Abstract
BACKGROUND
There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).
METHODS
This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.
RESULTS
The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001).
CONCLUSION
This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.
DOI: 10.1007/s40199-020-00353-w
PubMed: 32562159
PubMed Central: PMC7303568
Links to Exploration step
pubmed:32562159Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.</title><author><name sortKey="Vahedi, Ensieh" sort="Vahedi, Ensieh" uniqKey="Vahedi E" first="Ensieh" last="Vahedi">Ensieh Vahedi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ghanei, Mostafa" sort="Ghanei, Mostafa" uniqKey="Ghanei M" first="Mostafa" last="Ghanei">Mostafa Ghanei</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. mghaneister@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ghazvini, Ali" sort="Ghazvini, Ali" uniqKey="Ghazvini A" first="Ali" last="Ghazvini">Ali Ghazvini</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Azadi, Hossein" sort="Azadi, Hossein" uniqKey="Azadi H" first="Hossein" last="Azadi">Hossein Azadi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Izadi, Morteza" sort="Izadi, Morteza" uniqKey="Izadi M" first="Morteza" last="Izadi">Morteza Izadi</name><affiliation><nlm:affiliation>Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Panahi, Yunes" sort="Panahi, Yunes" uniqKey="Panahi Y" first="Yunes" last="Panahi">Yunes Panahi</name><affiliation><nlm:affiliation>Faculty of pharmacy, pharmacotherapy department, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Fathi, Saeid" sort="Fathi, Saeid" uniqKey="Fathi S" first="Saeid" last="Fathi">Saeid Fathi</name><affiliation><nlm:affiliation>University of Tehran, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Salesi, Mahmood" sort="Salesi, Mahmood" uniqKey="Salesi M" first="Mahmood" last="Salesi">Mahmood Salesi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Saadat, Seyed Hassan" sort="Saadat, Seyed Hassan" uniqKey="Saadat S" first="Seyed Hassan" last="Saadat">Seyed Hassan Saadat</name><affiliation><nlm:affiliation>Behavioral sciences research center, Lifestyle institute, Baqiatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ghazale, Amir Hossein" sort="Ghazale, Amir Hossein" uniqKey="Ghazale A" first="Amir Hossein" last="Ghazale">Amir Hossein Ghazale</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Rezapour, Mohammad" sort="Rezapour, Mohammad" uniqKey="Rezapour M" first="Mohammad" last="Rezapour">Mohammad Rezapour</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mozafari, Abolfazl" sort="Mozafari, Abolfazl" uniqKey="Mozafari A" first="Abolfazl" last="Mozafari">Abolfazl Mozafari</name><affiliation><nlm:affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Zand, Nahid" sort="Zand, Nahid" uniqKey="Zand N" first="Nahid" last="Zand">Nahid Zand</name><affiliation><nlm:affiliation>Department of Internal Medicine, Qom university of medical sciences, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Parsaei, Mohammadreza Raesi" sort="Parsaei, Mohammadreza Raesi" uniqKey="Parsaei M" first="Mohammadreza Raesi" last="Parsaei">Mohammadreza Raesi Parsaei</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ranjkesh, Mohammad Hossein" sort="Ranjkesh, Mohammad Hossein" uniqKey="Ranjkesh M" first="Mohammad Hossein" last="Ranjkesh">Mohammad Hossein Ranjkesh</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Jafari, Ramezan" sort="Jafari, Ramezan" uniqKey="Jafari R" first="Ramezan" last="Jafari">Ramezan Jafari</name><affiliation><nlm:affiliation>Department of Radiology and Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Movaseghi, Fatemeh" sort="Movaseghi, Fatemeh" uniqKey="Movaseghi F" first="Fatemeh" last="Movaseghi">Fatemeh Movaseghi</name><affiliation><nlm:affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Darabi, Enayat" sort="Darabi, Enayat" uniqKey="Darabi E" first="Enayat" last="Darabi">Enayat Darabi</name><affiliation><nlm:affiliation>School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32562159</idno><idno type="pmid">32562159</idno><idno type="doi">10.1007/s40199-020-00353-w</idno><idno type="pmc">PMC7303568</idno><idno type="wicri:Area/Main/Corpus">001360</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001360</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.</title><author><name sortKey="Vahedi, Ensieh" sort="Vahedi, Ensieh" uniqKey="Vahedi E" first="Ensieh" last="Vahedi">Ensieh Vahedi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ghanei, Mostafa" sort="Ghanei, Mostafa" uniqKey="Ghanei M" first="Mostafa" last="Ghanei">Mostafa Ghanei</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. mghaneister@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ghazvini, Ali" sort="Ghazvini, Ali" uniqKey="Ghazvini A" first="Ali" last="Ghazvini">Ali Ghazvini</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Azadi, Hossein" sort="Azadi, Hossein" uniqKey="Azadi H" first="Hossein" last="Azadi">Hossein Azadi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Izadi, Morteza" sort="Izadi, Morteza" uniqKey="Izadi M" first="Morteza" last="Izadi">Morteza Izadi</name><affiliation><nlm:affiliation>Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Panahi, Yunes" sort="Panahi, Yunes" uniqKey="Panahi Y" first="Yunes" last="Panahi">Yunes Panahi</name><affiliation><nlm:affiliation>Faculty of pharmacy, pharmacotherapy department, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Fathi, Saeid" sort="Fathi, Saeid" uniqKey="Fathi S" first="Saeid" last="Fathi">Saeid Fathi</name><affiliation><nlm:affiliation>University of Tehran, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Salesi, Mahmood" sort="Salesi, Mahmood" uniqKey="Salesi M" first="Mahmood" last="Salesi">Mahmood Salesi</name><affiliation><nlm:affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Saadat, Seyed Hassan" sort="Saadat, Seyed Hassan" uniqKey="Saadat S" first="Seyed Hassan" last="Saadat">Seyed Hassan Saadat</name><affiliation><nlm:affiliation>Behavioral sciences research center, Lifestyle institute, Baqiatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ghazale, Amir Hossein" sort="Ghazale, Amir Hossein" uniqKey="Ghazale A" first="Amir Hossein" last="Ghazale">Amir Hossein Ghazale</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Rezapour, Mohammad" sort="Rezapour, Mohammad" uniqKey="Rezapour M" first="Mohammad" last="Rezapour">Mohammad Rezapour</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mozafari, Abolfazl" sort="Mozafari, Abolfazl" uniqKey="Mozafari A" first="Abolfazl" last="Mozafari">Abolfazl Mozafari</name><affiliation><nlm:affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Zand, Nahid" sort="Zand, Nahid" uniqKey="Zand N" first="Nahid" last="Zand">Nahid Zand</name><affiliation><nlm:affiliation>Department of Internal Medicine, Qom university of medical sciences, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Parsaei, Mohammadreza Raesi" sort="Parsaei, Mohammadreza Raesi" uniqKey="Parsaei M" first="Mohammadreza Raesi" last="Parsaei">Mohammadreza Raesi Parsaei</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Ranjkesh, Mohammad Hossein" sort="Ranjkesh, Mohammad Hossein" uniqKey="Ranjkesh M" first="Mohammad Hossein" last="Ranjkesh">Mohammad Hossein Ranjkesh</name><affiliation><nlm:affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Jafari, Ramezan" sort="Jafari, Ramezan" uniqKey="Jafari R" first="Ramezan" last="Jafari">Ramezan Jafari</name><affiliation><nlm:affiliation>Department of Radiology and Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Movaseghi, Fatemeh" sort="Movaseghi, Fatemeh" uniqKey="Movaseghi F" first="Fatemeh" last="Movaseghi">Fatemeh Movaseghi</name><affiliation><nlm:affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Darabi, Enayat" sort="Darabi, Enayat" uniqKey="Darabi E" first="Enayat" last="Darabi">Enayat Darabi</name><affiliation><nlm:affiliation>School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences</title><idno type="eISSN">2008-2231</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Azithromycin (administration & dosage)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>Drug Combinations (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Iran (MeSH)</term><term>Length of Stay (MeSH)</term><term>Levofloxacin (administration & dosage)</term><term>Lopinavir (administration & dosage)</term><term>Male (MeSH)</term><term>Meropenem (administration & dosage)</term><term>Middle Aged (MeSH)</term><term>Naproxen (administration & dosage)</term><term>Oseltamivir (administration & dosage)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term><term>Prednisolone (administration & dosage)</term><term>Retrospective Studies (MeSH)</term><term>Ritonavir (administration & dosage)</term><term>Treatment Outcome (MeSH)</term><term>Vancomycin (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Levofloxacin</term><term>Lopinavir</term><term>Meropenem</term><term>Naproxen</term><term>Oseltamivir</term><term>Prednisolone</term><term>Ritonavir</term><term>Vancomycin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Iran</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32562159</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2008-2231</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences</Title><ISOAbbreviation>Daru</ISOAbbreviation></Journal><ArticleTitle>The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.</ArticleTitle><Pagination><MedlinePgn>507-516</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40199-020-00353-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vahedi</LastName><ForeName>Ensieh</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanei</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. mghaneister@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghazvini</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azadi</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izadi</LastName><ForeName>Morteza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panahi</LastName><ForeName>Yunes</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of pharmacy, pharmacotherapy department, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>Saeid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Tehran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salesi</LastName><ForeName>Mahmood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saadat</LastName><ForeName>Seyed Hassan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Behavioral sciences research center, Lifestyle institute, Baqiatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghazale</LastName><ForeName>Amir Hossein</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezapour</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozafari</LastName><ForeName>Abolfazl</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zand</LastName><ForeName>Nahid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Qom university of medical sciences, Qom, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsaei</LastName><ForeName>Mohammadreza Raesi</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranjkesh</LastName><ForeName>Mohammad Hossein</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Ramezan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology and Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Movaseghi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darabi</LastName><ForeName>Enayat</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Daru</MedlineTA><NlmUniqueID>101125969</NlmUniqueID><ISSNLinking>1560-8115</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>57Y76R9ATQ</RegistryNumber><NameOfSubstance UI="D009288">Naproxen</NameOfSubstance></Chemical><Chemical><RegistryNumber>6GNT3Y5LMF</RegistryNumber><NameOfSubstance UI="D064704">Levofloxacin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6Q205EH1VU</RegistryNumber><NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>FV9J3JU8B1</RegistryNumber><NameOfSubstance UI="D000077731">Meropenem</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064704" MajorTopicYN="N">Levofloxacin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077731" MajorTopicYN="N">Meropenem</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009288" MajorTopicYN="N">Naproxen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014640" MajorTopicYN="N">Vancomycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Length of stay in hospitals (ALOS)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32562159</ArticleId><ArticleId IdType="doi">10.1007/s40199-020-00353-w</ArticleId><ArticleId IdType="pii">10.1007/s40199-020-00353-w</ArticleId><ArticleId IdType="pmc">PMC7303568</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):648-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2007 Oct;13(10):1248-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17891146</ArticleId></ArticleIdList></Reference><Reference><Citation>Daru. 2020 Dec;28(2):789-793</Citation><ArticleIdList><ArticleId IdType="pubmed">32385829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 19;382(12):1177-1179</Citation><ArticleIdList><ArticleId IdType="pubmed">32074444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation><ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):64-68</Citation><ArticleIdList><ArticleId IdType="pubmed">32037389</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>New Microbes New Infect. 2020 Apr 22;35:100684</Citation><ArticleIdList><ArticleId IdType="pubmed">32322397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation><ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e13-e20</Citation><ArticleIdList><ArticleId IdType="pubmed">32283144</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapie. 2020 Jul - Aug;75(4):355-362</Citation><ArticleIdList><ArticleId IdType="pubmed">32418728</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2013 May;57(5):2231-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23459490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):425-434</Citation><ArticleIdList><ArticleId IdType="pubmed">32105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 May;94:74-77</Citation><ArticleIdList><ArticleId IdType="pubmed">32229257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Mar;8(3):e11-e12</Citation><ArticleIdList><ArticleId IdType="pubmed">32061335</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation><ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2020 Jun;53:38-42</Citation><ArticleIdList><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2019 Mar;17(3):181-192</Citation><ArticleIdList><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1851-1852</Citation><ArticleIdList><ArticleId IdType="pubmed">32187463</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Ann. 2014 Oct;43(10):417-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25290132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Jun;20(6):697-706</Citation><ArticleIdList><ArticleId IdType="pubmed">32224310</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cell Rev Rep. 2020 Jun;16(3):427-433</Citation><ArticleIdList><ArticleId IdType="pubmed">32281052</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2020 May;214:108408</Citation><ArticleIdList><ArticleId IdType="pubmed">32247038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2003 Sep 15;37(6):857-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12955652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Apr;26(4):465</Citation><ArticleIdList><ArticleId IdType="pubmed">32273604</ArticleId></ArticleIdList></Reference><Reference><Citation>HeartRhythm Case Rep. 2020 Apr 01;6(5):241-243</Citation><ArticleIdList><ArticleId IdType="pubmed">32363144</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2020 May;27(5):1451-1454</Citation><ArticleIdList><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2020 Jun;34(6):1503-1511</Citation><ArticleIdList><ArticleId IdType="pubmed">32372026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2006 Jun;129(6):1441-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16778260</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Mar;579(7798):265-269</Citation><ArticleIdList><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32562159
|texte= The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32562159" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |